Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study

Arianna Di Stadio; Evanthia Bernitsas; Domenico Antonio Restivo; Enrico Alfonsi; Rosario Marchese-Ragona

doi:10.1016/j.jvoice.2018.01.002

Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study

Arianna Di Stadio, Evanthia Bernitsas, Domenico Antonio Restivo, Enrico Alfonsi, Rosario Marchese-Ragona

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation. Materials and methods: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A. Results: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6–8 months. Conclusions: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

Original language	English
Journal	Journal of Voice
DOIs	https://doi.org/10.1016/j.jvoice.2018.01.002
Publication status	Accepted/In press - Jan 1 2018

Keywords

Botulin toxin A
Dysphonia
Multiple sclerosis
Spasmodic dysphonia
Treatment

ASJC Scopus subject areas

Otorhinolaryngology
Speech and Hearing
LPN and LVN

Access to Document

10.1016/j.jvoice.2018.01.002

Cite this

@article{75af42388c284e47a47e741780f452b8,

title = "Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study",

abstract = "Objectives: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation. Materials and methods: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A. Results: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6–8 months. Conclusions: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.",

keywords = "Botulin toxin A, Dysphonia, Multiple sclerosis, Spasmodic dysphonia, Treatment",

author = "{Di Stadio}, Arianna and Evanthia Bernitsas and Restivo, {Domenico Antonio} and Enrico Alfonsi and Rosario Marchese-Ragona",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/j.jvoice.2018.01.002",

language = "English",

journal = "Journal of Voice",

issn = "0892-1997",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A

T2 - A Pilot Study

AU - Di Stadio, Arianna

AU - Bernitsas, Evanthia

AU - Restivo, Domenico Antonio

AU - Alfonsi, Enrico

AU - Marchese-Ragona, Rosario

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation. Materials and methods: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A. Results: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6–8 months. Conclusions: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

AB - Objectives: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation. Materials and methods: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A. Results: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6–8 months. Conclusions: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

KW - Botulin toxin A

KW - Dysphonia

KW - Multiple sclerosis

KW - Spasmodic dysphonia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85045081058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045081058&partnerID=8YFLogxK

U2 - 10.1016/j.jvoice.2018.01.002

DO - 10.1016/j.jvoice.2018.01.002

M3 - Article

AN - SCOPUS:85045081058

JO - Journal of Voice

JF - Journal of Voice

SN - 0892-1997

ER -

Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this